Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Glucose Transporters

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:

Negative and Cognitive Symptoms of Schizophrenia

Negative and Cognitive Symptoms of Schizophrenia

Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...

Type I Diabetes III: Clinical Manifestations

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...

Hyperglycemia

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...

Psychological and Sociocultural Causes of Schizophrenia

Psychological and Sociocultural Causes of Schizophrenia

Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...

Overview of Carbohydrate Metabolism

Overview of Carbohydrate Metabolism

Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Brain correlates of cognitive reserve in offspring of patients with schizophrenia or bipolar disorder.

European child & adolescent psychiatry·2026

Same author

Two decades of progress in schizophrenia: Evolution, current insights, and future directions.

Spanish journal of psychiatry and mental health·2026

Same author

Negative symptoms in schizophrenia: Methodological challenges and emerging solutions for outcome measurement.

Neuroscience applied·2026

Same author

Longitudinal Impact of Birthweight and its Polygenic Risk Score on Glucose and Antipsychotic-Induced Weight Gain in First Episode Psychosis.

Schizophrenia bulletin·2026

Same author

Subjective perceptions of negative symptoms among outpatients with schizophrenia and their relatives or caregivers: Definitions, importance, measurement, and desired improvement.

Schizophrenia research·2026

Same author

Impact of Obstetric Complications in Subjects at Clinical High Risk for Psychosis: A Systematic Review and Meta-Analysis.

Acta psychiatrica Scandinavica·2026

Search research articles

Related Experiment Video

Updated: Jun 27, 2026

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

Differences in glucose tolerance between deficit and nondeficit schizophrenia.

Brian Kirkpatrick¹, Emilio Fernandez-Egea, Clemente Garcia-Rizo

¹Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, Georgia 30912, USA. bkirkpatrick2@aol.com

Schizophrenia Research

|December 3, 2008

Summary

People with deficit schizophrenia show better glucose tolerance than those with nondeficit schizophrenia, suggesting distinct biological differences. This finding highlights the importance of differentiating schizophrenia subtypes for understanding associated health risks like diabetes.

More Related Videos

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

Published on: January 7, 2018

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

Related Experiment Videos

Last Updated: Jun 27, 2026

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

Published on: January 7, 2018

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

Area of Science:

Neuroscience
Metabolic Disorders
Psychiatry

Background:

Schizophrenia is linked to increased diabetes risk, potentially independent of medication.
Deficit schizophrenia, marked by persistent negative symptoms, presents unique characteristics compared to nondeficit schizophrenia.
Existing research indicates differences in illness course, treatment, risk factors, and biology between deficit and nondeficit schizophrenia.

Purpose of the Study:

To investigate whether individuals with deficit schizophrenia and nondeficit schizophrenia differ in glucose tolerance.
To explore potential distinct etiopathophysiologies between schizophrenia subtypes regarding metabolic health.

Main Methods:

A 75g oral glucose tolerance test (GTT) was administered to newly diagnosed, antipsychotic-naïve subjects with nonaffective psychosis.
Subjects were categorized into deficit schizophrenia, nondeficit schizophrenia, and matched control groups.
Two-hour glucose concentrations were measured and compared across the groups.

Main Results:

Nondeficit schizophrenia patients exhibited significantly higher two-hour glucose concentrations compared to both deficit schizophrenia patients and control subjects.
Deficit schizophrenia patients also showed significantly higher two-hour glucose concentrations than control subjects.
These findings indicate a gradient of glucose intolerance across the groups: nondeficit > deficit > controls.

Conclusions:

The study provides evidence that deficit and nondeficit schizophrenia subtypes differ in glucose tolerance.
These metabolic differences support the hypothesis of a distinctive etiopathophysiology for the deficit schizophrenia group.
Further research into these biological distinctions may inform targeted interventions for metabolic comorbidities in schizophrenia.